Intuitive Surgical’s Growth Trajectory Gains Momentum with Key FDA Approval

The leader in robotic-assisted surgery is currently demonstrating robust performance, supported by impressive quarterly results and significant strategic advancements. Market experts have recently upgraded their assessments, bringing particular attention to the company’s latest regulatory clearance for cardiac procedures in the United States. Investors are now evaluating the potential impact of this new market segment on the firm’s growth for the current year.

Strategic Milestone Unlocks New Potential

A major catalyst for future expansion arrived in January 2026, when the U.S. Food and Drug Administration (FDA) granted clearance for the da Vinci 5 system to be used in cardiological interventions. This decision opens access to a substantial new market. Company management estimates that approximately 160,000 additional annual procedures in the United States and South Korea alone could become addressable for this technology. The rollout for these complex surgeries is planned to be measured, ensuring quality in clinical application.

This development has resonated within the financial community. The analysis firm Zacks Research recently elevated its rating for the company from “Hold” to “Strong Buy.” Despite these positive developments, the shares closed at 427.55 euros, still down roughly 10.8% since the start of the year—a position that may not yet fully reflect the recent upward trend.

Financial Performance Exceeds Projections

The prevailing optimism is grounded in solid operational results from the fourth quarter of 2025. Intuitive Surgical reported revenue growth of 18.8%, reaching $2.87 billion and comfortably surpassing market expectations. Adjusted earnings per share also outperformed analyst forecasts, coming in at $2.53.

Should investors sell immediately? Or is it worth buying Intuitive Surgical?

This momentum is not solely driven by the core business of the established da Vinci robotic systems. The Ion system for lung biopsies is showing accelerated adoption, with procedure volume increasing by 44% year-over-year. This highlights the success of the management’s strategy to broaden its portfolio beyond general surgery.

Competitive Landscape and 2026 Outlook

Despite its dominant market position, the company faces growing competitive pressure from platforms developed by Medtronic and Johnson & Johnson. To defend its market share, Intuitive Surgical is accelerating its expansion into ambulatory surgery centers. While company insiders sold shares worth approximately $30.8 million in the past quarter, institutional investor confidence remains high, with an ownership stake exceeding 83%.

For the 2026 fiscal year, company leadership forecasts worldwide growth for da Vinci procedures in the range of 13% to 15%. It aims to maintain a stable gross margin between 67% and 68%. The installed base of systems continued to expand, surpassing 11,100 units globally by the end of 2025. This growing footprint further solidifies the foundation for recurring revenue from service and instrument sales.